BriaCell transfers exclusive sCD80 license to BriaPro; receives 23.97M shares, increases stake to 78%

BriaCell Therapeutics Corp.

BriaCell transfers exclusive license for Soluble CD80 to BriaPro for 23,972,589 BriaPro shares, increasing stake to ~78%.
BriaCell provides up to $3M credit facility to BriaPro for R&D; each drawdown subject to BriaCell approval.
Transaction expected to close March 12, 2026, subject to disinterested shareholder approval and independent valuation.
License originally from University of Maryland Baltimore County; sCD80 showed anti-tumor activity in animal models.
BriaPro stock valued at approx. C$1.18M aggregate; BriaPro to pay 2% royalties to UMBC upon commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.